AstraZeneca
NEWS
They are calling the combination of tremelimumab and Imfinzi the STRIDE regimen for Single Tremelimumab Regular Interval Durvalumab.
Four leading pharmaceutical companies partnered with Amazon Web Services and Israel Biotech Fund to launch AION Labs, an innovation space that will allow drug developers to harness AI and computational science to solve therapeutic challenges.
Research on the ever-evolving SARS-CoV-2 virus continues as scientists scramble to make sense of it and find cures. Here’s a look.
This year – 2021 – will be a transformational year, Rosen predicted, citing three important milestones.
AstraZeneca submitted data for an Emergency Use Authorization for AZD7442, a long-acting antibody combination from B-cells donated by patients who recovered from COVID-19.
The DOL’s Office of Federal Contract Compliance Programs found that AstraZeneca paid a much lower base salary than similar employees to 23 Hispanic female staff and 295 female employees.
The FDA granted the latest designation based on the Phase III DESTINY-Breast03 trial on adult patients diagnosed with unresectable or metastatic HER2-positive breast cancer.
Data from the Phase II CYPRESS study presented at the virtual IDWeek (Infectious Disease Week) 2021 showed that the vaccine candidate provided a robust response against the infection.
It was a busy week for clinical trial news. Here’s a look.
JOBS
IN THE PRESS